4/1
07:12 am
inmb
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study [Yahoo! Finance]
Low
Report
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study [Yahoo! Finance]
4/1
07:00 am
inmb
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
Low
Report
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
3/27
04:05 pm
inmb
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
Low
Report
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
3/24
10:58 am
inmb
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 [Yahoo! Finance]
Low
Report
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 [Yahoo! Finance]
3/24
08:00 am
inmb
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
Low
Report
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
2/20
08:27 am
inmb
INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% [Yahoo! Finance]
Medium
Report
INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% [Yahoo! Finance]
2/13
06:16 pm
inmb
INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Maxim Group from $22.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Maxim Group from $22.00 to $30.00. They now have a "buy" rating on the stock.
2/12
10:18 am
inmb
INmune Bio price target raised to $23 from $22 at Scotiabank [Yahoo! Finance]
Low
Report
INmune Bio price target raised to $23 from $22 at Scotiabank [Yahoo! Finance]
2/12
07:00 am
inmb
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
High
Report
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
2/11
09:57 am
inmb
INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Scotiabank from $22.00 to $23.00. They now have a "sector outperform" rating on the stock.
Medium
Report
INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Scotiabank from $22.00 to $23.00. They now have a "sector outperform" rating on the stock.
2/10
07:37 am
inmb
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) [Yahoo! Finance]
Medium
Report
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) [Yahoo! Finance]
2/10
07:00 am
inmb
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Medium
Report
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
1/29
05:43 am
inmb
INmune Bio, Inc. (NASDAQ: INMB) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
High
Report
INmune Bio, Inc. (NASDAQ: INMB) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
1/28
08:00 am
inmb
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
Low
Report
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
1/28
07:17 am
inmb
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $23.00 price target on the stock.
Medium
Report
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $23.00 price target on the stock.